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Statement of findings
Using semiquantitative reverse transcription-polymerase chain reaction assays, we
investigated the expression of variant messenger RNAs relative to wild-type estrogen
receptor (ER)-a messenger RNA in normal breast tissues and their adjacent matched breast
tumor tissues. Higher ER variant truncated after sequences encoding exon 2 of the wild-type
ER-a (ERC4) messenger RNA and a lower exon 3 deleted ER-a variant (ERD3) messenger
RNA relative expression in the tumor compartment were observed in the ER-positive/PR-
positive and the ER-positive subsets, respectively. A significantly higher relative expression
of exon 5 deleted ER-a varient (ERD5) messenger RNA was observed in tumor components
overall. These data demonstrate that changes in the relative expression of ER-a variant
messenger RNAs occur between adjacent normal and neoplastic breast tissues. We
suggest that these changes might be involved in the mechanisms that underlie breast
tumorigenesis.
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dCTP = deoxycytidine triphosphate; ER = estrogen receptor; ERC4 = estrogen receptor variant truncated after sequences encoding exon 2 of
the wild-type estrogen receptor-a; ERD3 = exon 3 deleted estrogen receptor-a variant; ERD5 = exon 5 deleted estrogen receptor-a variant;
PCR = polymerase chain reaction; PR = progesterone receptor; WT = wild-type.
Introduction: Estrogen receptor (ER)-a and ER-b are believed
to mediate the action of estradiol in target tissues. Several
ER-a and ER-b variant messenger RNAs have been identified
in both normal and neoplastic human tissues. Most of these
variants contain a deletion of one or more exons of the wild-
type (WT) ER messenger RNAs. The putative proteins that are
encoded by these variant messenger RNAs would therefore be
missing some functional domains of the WT receptors, and
might interfere with WT-ER signaling pathways. The detection
of ER-a variants in both normal and neoplastic human breast
tissues raised the question of their possible role in breast
tumorigenesis.
We have previously reported an increased relative expres-
sion of exon 5 deleted ER-a variant (ERD5) messenger RNA
and of another ER-a variant truncated of all sequences
following the exon 2 of the WT ER-a (ERC4) messenger
RNA in breast tumor samples versus independent normal
breast tissues. In contrast, a decreased relative expression
of exon 3 deleted ER-a variant (ERD3) messenger RNA in
tumor tissues and cancer cell lines versus independent
normal reduction mammoplasty samples has recently been
reported. These data were obtained in tissues from different
individuals and possible interindividual differences cannot be
excluded.
Aims: The goal of this study was to investigate the expressions
of ERC4, ERD5 and ERD3 variant messenger RNAs in normal
breast tissues and their matched adjacent primary breast tumor
tissues.
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Materials and methods: Eighteen cases were selected from
the Manitoba Breast Tumor Bank, which had well separated
and histopathologically characterized normal and adjacent
neoplastic components. All tumors were classified as primary
invasive ductal carcinomas. Six tumors were ER-
negative/progesterone receptor (PR)-negative, nine were ER-
positive/PR-positive, two were ER-positive/PR-negative, and
one was ER-negative/PR-positive, as measured by ligand-
binding assay. For each specimen, total RNA was extracted
from frozen normal and tumor tissue sections and was reverse
transcribed. The expressions of ERC4, ERD3 and ERD5
messenger RNAs relative to WT ER-a messenger RNA were
investigated by previously validated semiquantitative reverse
transcription polymerase chain reaction (PCR) assays
performed using three different sets of primers.
Results: As shown Figure 1a, two PCR products were
obtained that corresponded to WT ER and ERC4 messenger
RNAs. For each case, the mean of the ratios obtained in at
least three independent PCR experiments is shown for both
normal and tumor compartments (Fig 1b). A statistically higher
ERC4 messenger RNA relative expression was found in the
neoplastic components of ER-positive/PR-positive tumors, as
compared with matched adjacent normal tissues (n = 9; P =
0.019, Wilcoxon signed-rank test).
Two PCR products were obtained that corresponded to WT-
ER and ERD3 messenger RNAs (Fig 2a). A significantly higher
expression of ERD3 messenger RNA was observed in the
normal compared with the adjacent neoplastic components of
ER-positive subset (n=8;  P=0.023, Wilcoxon signed-rank
test; Fig 2b).
Two PCR products were obtained that corresponded to WT-
ER and ERD5 complementary DNAs (Fig 3a). As shown in
Figure 3b, a statistically significant higher relative expression of
ERD5 messenger RNA was observed in tumor components
when this expression was measurable in both normal and
adjacent tumor tissues (n=15;  P=0.035, Wilcoxon signed-
rank test).
Discussion: A statistically significant higher ERC4 messenger
RNA expression was found in ER-positive/PR-positive tumors
as compared with matched normal breast tissues. ERC4
variant messenger RNA has previously been demonstrated to
be more highly expressed in ER-positive tumors that showed
poor as opposed to tumors that showed good prognostic
characteristics. Interestingly, we also have reported similar
levels of expression of ERC4 messenger RNA in primary breast
tumors and their concurrent axillary lymph node metastases.
Taken together, these data suggest that the putative role of the
ERC4 variant might be important at different phases of breast
tumorigenesis and tumor progression; alteration of ERC4
messenger RNA expression and resulting modifications in ER
signaling pathway probably occur before breast cancer cells
acquire the ability to metastasize. Transient expression assays
revealed that the protein encoded by ERC4 messenger RNA
was unable to activate the transcription of an estrogen-
responsive element-reporter gene or to modulate the wild-type
ER protein activity. The biologic significance of the changes
observed in ERC4 messenger RNA expression during breast
tumorigenesis remains to be determined.
A higher relative expression of ERD3 messenger RNA in the
normal breast tissue components compared with adjacent
neoplastic tissue was found in the ER-positive subgroup.
Figure 1
Comparison of the relative expression of estrogen receptor (ER)
variant truncated after sequences encoding exon 2 of the wild-type
(WT) ER-a (ERC4) messenger RNAs between breast tumor and
adjacent matched normal breast samples. (A) Total RNA extracted
from frozen tissue sections from tumor (T) and adjacent normal (N)
breast tissue samples was reverse transcribed and polymerase chain
reaction (PCR) was amplified using ERU, ERL and C4L primers (see
text). Radioactive PCR products were separated on a 6% acrylamide
gel and visualized by autoradiography. Bands migrating at 149 and
536 base pairs were identified as corresponding to WT-ER and ERC4
variant messenger RNA, respectively. C, negative control (no
complementary DNA added during the PCR reaction). (B) For each
case, signals corresponding to ERC4 variant messenger RNA were
quantified (see text) and expressed in arbitrary units for tumor (black
column) and normal (white column) components. For each sample, the
mean and the standard deviation of at least three different PCR assays
are indicated. Cases are sorted by ER status (black bottom lane) and
progesterone receptor (PR) status (gray bottom lane). The significance
of the differences between tumor and normal matched components
within each subgroup, as tested using the Wilcoxon matched-pair test,
is indicated where P < 0.05. M, molecular weight marker (fx174 HaeIII
digest; Gibco BRL, Grand Island, New York, NY).Breast Cancer Research    Vol 2 No 1 Leygue et al
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These data are in agreement with the recently published report
of Erenburg et al, who showed a decreased relative expression
of ERD3 messenger RNA in neoplastic breast tissues
compared with independent reduction mammoplasty and
breast tumor. Transfection experiments showed that the
activation of the transcription of the pS2 gene by estrogen was
drastically reduced in the presence of increased ERD3
expression. The authors hypothesized that the reduction in
ERD3 expression could be a prerequisite for breast
carcinogenesis to proceed.
We observed a significantly higher relative expression of
ERD5 messenger RNA in breast tumor components
compared with matched adjacent normal breast tissue. These
data confirm our previous observations performed on
Figure 2
Comparison of the relative expression of exon 3 deleted estrogen
receptor (ER) variant (ERD3) messenger RNA between breast tumor
and adjacent matched normal breast samples. (A) Total RNA extracted
from frozen tissue sections from tumor (T) and adjacent normal (N)
breast tissue samples was reverse transcribed and polymerase chain
reaction (PCR) was amplified using D3U and D3L primers. Radioactive
PCR products were separated on a 6% acrylamide gel and visualized
by autoradiography. Bands migrating at 354 and 237 base pairs were
identified as corresponding to wild-type (WT)-ER and ERD3 variant
messenger RNA, respectively. C, negative control (no complementary
DNA added during the PCR reaction). (B) For each case, signals
corresponding to ERD3 variant messenger RNA were quantified and
expressed in arbitrary units for tumor (black column) and normal (white
column) components. For each sample, the mean and the standard
deviation of at least three different polymerase chain reaction (PCR)
assays are indicated. Cases are sorted by ER status (black bottom
lane) and progesterone receptor (PR) status (gray bottom lane).
Samples that failed to have three measurable signals in the four
experiments performed in both normal and neoplastic components
were not included in the statistical analysis. The significance of the
differences between tumor and normal matched components within
each subgroup, as tested using the Wilcoxon matched-pair test, is
indicated where P < 0.05. M, molecular weight marker.
Figure 3
Comparison of the relative expression of exon 3 deleted estrogen
receptor (ER) variant (ERD3) messenger RNA between breast tumor
and adjacent matched normal breast samples. (A) Total RNA extracted
from frozen tissue sections from tumor (T) and adjacent normal (N)
breast tissue samples was reverse transcribed and polymerase chain
reaction (PCR) amplified using D5U and D5L primers. Radioactive
PCR products were separated on a 6% acrylamide gel and visualized
by autoradiography. Bands that migrated at 483 and 344 base pairs
were identified as corresponding to wild-type (WT)-ER and exon 5
deleted ER variant (ERD5) messenger RNA, respectively. C, negative
control (no complementary DNA added during the PCR reaction). (B)
For each case, signals corresponding to ERD5 variant messenger
RNA were quantified and expressed in arbitrary units for tumor (black
column) and normal (white column) components. For each sample, the
mean and the standard deviation of at least three different PCR assays
are indicated. Cases are sorted by ER status (black bottom lane) and
progesterone receptor (PR) status (gray bottom lane). Samples that
failed to have three measurable signals in the four experiments
performed in both normal and neoplastic components were not
included in the statistical analysis. The significance of the differences
between tumor and normal matched components within each
subgroup, as tested using the Wilcoxon matched-pair test, is indicated
where P < 0.05. M, molecular weight marker.Full article
unmatched normal and neoplastic human breast tissues.
Upregulated expression of this variant has already been
reported in ER-negative/PR-positive tumors, as compared
with ER-positive/PR-positive tumors, suggesting a possible
correlation between ERD5 messenger RNA expression and
breast tumor progression. Even though it has been suggested
that ERD5 could be related to the acquisition of insensitivity to
antiestrogen treatment (ie tamoxifen), accumulating data
refute a general role for ERD5 in hormone-resistant tumors.
Only ER-positive pS2-positive tamoxifen-resistant tumors have
been shown to express significantly higher levels of ERD5
messenger RNA, as compared with control tumors. Taken
together, these data suggest that the exact biologic
significance of ERD5 variant expression during breast
tumorigenesis and breast cancer progression, if any, remains
unclear.
In conclusion, we have shown that the relative expressions of
ERC4 and ERD5 variant messenger RNAs were increased in
human breast tumor tissue, as compared with normal adjacent
tissue, whereas the expression of ERD3 variant messenger
RNA was decreased in breast tumor tissues. These results
suggest that the expressions of several ER-a variant
messenger RNAs are deregulated during human breast
tumorigenesis. Further studies are needed to determine
whether these changes are transposed at the protein level.
Furthermore, the putative role of ER-a variants in the
mechanisms that underlie breast tumorigenesis remains to be
determined.
Introduction
Estrogen receptor (ER)-a and ER-b are believed to
mediate the action of estradiol in target tissues [1,2].
These two receptors, which belong to the steroid/retinoic
acid/thyroid receptor superfamily [3], contain several
structural and functional domains [4] that are encoded by
two messenger RNAs that contain eight exons [5,6].
Upon ligand binding, ER-a and ER-b proteins recognize
specific estrogen-responsive elements located in DNA in
the proximity of target genes, and through interactions
with several coactivators modulate the transcription of
these genes [7].
Several ER-a and ER-b variant messenger RNAs have
been identified in both normal and neoplastic human
tissues [8–12]. Most of these variants contain a deletion of
one or more exons of the wild-type (WT)-ER messenger
RNA. The putative proteins encoded by these variant mes-
senger RNAs would therefore be missing some functional
domains of the WT receptors and might interfere with WT-
ER signaling pathways. Indeed, in vitro functional studies
have shown that some recombinant ER-a variant proteins
can affect estrogen-regulated gene transcription. For
example, the variant protein encoded by exon 3 deleted
ER-a variant (ERD3) messenger RNA, which is missing the
second zinc finger of the DNA binding domain, has been
shown [13] to have a dominant negative activity on WT-
ER-a receptor action. A similar dominant negative activity
has been observed for ERD5 variant protein (encoded by
an ER-a variant messenger RNA deleted in exon 5
sequences), which is missing a part of the hormone-
binding domain of the WT molecule [14]. Interestingly, a
constitutive hormone-independent activity [15] and a WT
enhancing activity [16] have also been attributed to ERD5
variant protein in different systems. The relevance of the
levels achieved in these transfection experiments to in vivo
expression remains unclear. It should also be noted that
these functional activities are likely to be cell-type and pro-
moter specific [8].
The discovery that these ER-a variants are expressed in
both normal and neoplastic human breast tissues,
however, raised the question of their possible role in
breast tumorigenesis [8]. We have previously reported an
increased relative expression of ERD5 messenger RNA
and of ERC4 messenger RNA, another ER-a variant mes-
senger RNA that is truncated of all sequences following
the exon 2 of the WT ER-a [17], in breast tumor samples
versus independent normal breast tissues [18,19]. In con-
trast, Erenburg et al [20] recently reported a decreased
relative expression of ERD3 messenger RNA in tumor
tissues and cancer cell lines versus independent normal
reduction mammoplasty samples. Those data, which sug-
gested that alteration in ERD5, ERD3 and clone 4 mes-
senger RNA expression might occur during breast
tumorigenesis, were obtained in tissues from different indi-
viduals, and possible interindividual differences cannot be
excluded.
In order to clarify this issue, we investigated the expres-
sion of these three variant messenger RNAs in normal
breast tissues and their matched adjacent primary breast
tumor tissues.
Materials and methods
Human breast tissues and reverse transcription
In order to investigate the expressions of ERC4, ERD3
and ERD5 messenger RNA relative to WT-ER messenger
RNA within matched normal and breast tumor tissues,
eighteen cases were selected in the National Cancer Insti-
tute of Canada Manitoba Breast Tumor Bank (Winnipeg,
Manitoba, Canada), which had well separated and
histopathologically characterized normal and adjacent
neoplastic components. The Tumor Bank, which serves as
http://breast-cancer-research.com/content/2/1/064
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a national Tumor Bank and is funded by the National
Cancer Institute of Canada, has been reviewed and
received approval from the Ethics Review Committee,
Faculty of Medicine, University of Manitoba.
The processing of specimens collected in the Manitoba
Breast Tumor Bank has already been described [21].
Briefly, each specimen had been rapidly frozen as soon as
possible after surgical removal. A portion of the frozen
tissue block was processed to create a paraffin-embed-
ded tissue block that was matched and oriented relative to
the remaining frozen block. These paraffin blocks provide
high quality histologic sections, which are used for patho-
logic interpretation and assessment, and are mirror
images of the frozen sections used for RNA extractions.
For each case, tumor and adjacent normal tissues from
the same individual were histologically characterized by
observation of paraffin sections. The presence of normal
ducts and lobules, as well as the absence of any atypical
lesion, were confirmed in all normal tissue specimens. All
tumor components were classified as primary invasive car-
cinomas. Seven tumors were ER-negative (ER
<3 fmol/mg protein), with progesterone receptor (PR)
values ranging from 2.2 to 11.2 fmol/mg protein, as mea-
sured using ligand-binding assay [22]. Axillary nodal
metastases were observed in five of these cases. Eleven
tumors were ER-positive (ER values ranged from 3.5 to
159 fmol/mg protein), with PR values ranging from 5.8 to
134 fmol/mg protein. These tumors spanned a wide range
of grades (grades 5–9, median 7.5), which were deter-
mined using the Nottingham grading system [23]. Axillary
nodal metastases were observed in one of these cases.
Patients were from 39 to 86 years old (median 54 years).
Total RNA was extracted from frozen tissue sections and
reverse-transcribed in a final volume of 25 ml as previously
described [18]. The quality of complementary DNAs
obtained was assessed by amplification of the ubiqui-
tously expressed glyceraldehyde-3-phosphate dehydroge-
nase complementary DNA, as described previously [18].
Triple primer polymerase chain reaction
A previously described triple primer polymerase chain reac-
tion (PCR) assay has been used to coamplify ERC4 and
WT-ER-a complementary DNAs [19,24]. Primers used con-
sisted of ERU primer (5¢-TGTGCAATGACTATGCTTCA-3¢,
sense, located in WT-ER exon 2, position 792–811), ERL
primer (5¢-GCTCTTCCTCCTGTTTTTAT-3¢, antisense,
located in WT-ER exon 3, position 940–921), and C4L
primer (5¢-TTTCAGTCTTCAGATACCCCAG-3¢, antisense,
located in ERC4 sequence, position 1336–1315). The
given positions correspond to the published sequences for
WT-ER [1] and ERC4 [17].
PCR amplifications were performed as previously
described [18,24]. Briefly, 0.2 ml reverse transcription
mixture was amplified in a final volume of 15 ml, in the
presence of 1.5 mCi of [a-32P] deoxycytidine triphosphate
(dCTP; 3000 Ci/mmol), 4 ng/ml of each primer and 0.3
unit of Taq DNA polymerase. Each cycle consisted of
1 min at 94°C, 30 s at 60°C and 1 min at 72°C. PCR
products were then separated on 6% polyacrylamide gels
containing 7 mol/l urea (polyacrylamide gel electrophore-
sis). After electrophoresis, the gels were dried and autora-
diographed. Two PCR products were obtained, which
were identified by subcloning and sequencing, performed
as previously described [18]. PCR products migrating
with the apparent size of 149 and 536 base pairs were
shown to correspond to WT-ER and ERC4 complemen-
tary DNAs, respectively.
Polymerase chain reaction
Two different primer sets, ERD3 and ERD5, were used to
coamplify WT-ER and ERD3 complementary DNAs, and
WT-ER and ERD5 complementary DNAs, respectively.
ERD3 primer set consisted of D3U primer (5¢-TGTGCAAT-
GACTATGCTTCA-3¢, sense, located in WT-ER exon 2,
position 792–811) and D3L primer (5¢-TGTTCTTCTTA-
GAGCGTTTGA-3¢, antisense, located in WT-ER exon 4,
position 1145–1125). ERD5 primer set consisted of D5U
primer (5¢-CAGGGGTGAAGTGGGGTCTGCTG-3¢, sense,
located in WT-ER exon 4, position 1060–1082) and D5L
primer (5¢-aTGCGGAACCGAGATGATGTAGC-3¢, anti-
sense, located in WT-ER exon 6, position 1542–1520). The
given positions correspond to published sequences for WT-
ER [1].
PCR amplifications were performed and PCR products
analyzed as previously described [18]. Briefly, 0.2 ml
reverse transcription mixture was amplified in a final
volume of 15 ml, in the presence of 1.5 mCi of [a-32P]
dCTP (3000 Ci/mmol), 4 ng/ml of each primer of the
primer set considered (ERD3 or ERD5 primer set) and
0.3 unit of Taq DNA polymerase. Each cycle consisted of
30 s at 94°C, 30 s at 60°C and 30 s at 72°C. PCR prod-
ucts were then separated on 6% polyacrylamide gels con-
taining 7 mol/l urea (polyacrylamide gel electrophoresis).
Following electrophoresis, the gels were dried and autora-
diographed. For each PCR, two PCR products were
obtained, which were identified by subcloning and
sequencing. PCR products migrating with the apparent
size of 354 and 483 base pairs, using ERD3 and ERD5
primer set, respectively, were shown to correspond to
WT-ER complementary DNA. PCR products migrating
with the apparent size of 237 and 344 base pairs, using
ERD3 and ERD5 primer set, were shown to correspond to
ERD3 and ERD5 complementary DNAs, respectively.
Quantitation and statistical analysis
For each experiment, bands corresponding to the variant
messenger RNA (ie ERC4, ERD3 or ERD5) and to WT-
ER were excised from the gel and counted in a scintillationcounter. For each set of primers (ie ERC4, ERD3 and
ERD5 primer set) and for each sample, four independent
PCR assays were performed. The ratios between ERC4,
ERD3 or ERD5 signals and corresponding WT-ER signal
were calculated. For each experiment, in order to correct
for overall interassay variations (due to different batches of
radiolabelled [a-32P] dCTP or of Taq DNA polymerase),
the ratio observed in the same particular tumor (case
number 12) was arbitrarily given the value of one and all
other ratios expressed relatively. Under our experimental
conditions, some samples did not have measurable levels
(ie signal lower than twice the background value) of ERD3
or ERD5 variant messenger RNAs (see Figs 2a and 3a) in
any of the four repetitions performed. Only cases that had
detectable levels in at least three of the replicates in both
their normal and tumor compartments were included in the
statistical analysis. The significance of the differences in
the relative levels of expression of ERC4, ERD3 and
ERD5 messenger RNAs between matched normal and
tumor components was determined using the Wilcoxon
signed-rank test.
Results
Relative expression of ERC4 messenger RNA in matched
normal and breast tumor tissues
A recently described triple-primer PCR assay was used to
compare the relative expressions of ERC4 messenger
RNA between adjacent normal and tumor components
[19,24]. In this assay, three primers are used simultane-
ously during the PCR: the upper primer is able to recog-
nize both WT-ER and ERC4 complementary DNA
sequences, whereas the two lower primers are specific for
each complementary DNA. Competitive amplification of
two PCR products occurs, giving a final PCR product
ratio related to the initial input of target complementary
DNAs. This approach has been validated previously both
by competitive amplification of spiked complementary
DNA preparations [19] and by comparison to RNAse pro-
tection assays [24].
As shown Figure 1a, two PCR products were obtained,
which migrated at the apparent size of 149 and 536 base
pairs. These products have been shown to correspond to
WT-ER and ERC4 messenger RNAs, respectively [24].
One should note the presence, in samples where WT-ER
and ERC4 signals are high (Fig 1a, lane 5), of minor addi-
tional bands, one of which has been previously identified
as corresponding to exon 2-duplicated ER-a variant com-
plementary DNA [24]. The presence of these minor PCR
products did not interfere with the quantitative aspect of
the triple-primer PCR assay [24]. For each case, the mean
of the ratios obtained in at least three independent PCR
experiments, expressed in arbitrary units, is shown for both
normal and tumor compartments (Fig 1b). A higher clone
4 messenger RNA relative expression in the tumor com-
partment was observed in 12 out of 18 cases. This differ-
ence did not, however, reach statistical significance
(P = 0.47, Wilcoxon signed-rank test). When considering
only the ER-positive/PR-positive subset (n = 9), as mea-
sured by the ligand-binding assay, a statistically higher
ERC4 messenger RNA relative expression was found in
the neoplastic components, as compared with matched
adjacent normal tissues (P = 0.019, Wilcoxon signed-rank
test).
Relative expression of ERD3 messenger RNA in matched
normal and breast tumor tissues
A PCR assay, performed using primers annealing to
sequences in exons 2 and 4, was used to investigate
ERD3 messenger RNA expression relative to WT-ER in
these 18 matched cases. We [18] and others [25] have
previously shown that the coamplification of WT-ER and
an exon-deleted ER-a variant complemetary DNA resulted
in the amplification of two PCR products, the relative
signal intensity of which provided a previously validated
measurement of exon-deleted ER-a variant expression.
Two PCR products were obtained, that migrated with an
apparent size of 354 and 237 base pairs (Fig 2a). These
fragments were shown by subcloning and sequencing to
correspond to WT-ER and ERD3 messenger RNAs (data
not shown). The relative ERD3 signal was measurable in
the normal and in the tumor compartments of 13 cases
(Fig 2b). Out of these 13 cases, ERD3 messenger RNA
expression was higher in the normal compartment in 10
cases. This difference, however, did not reach statistical
significance (P = 0.057, Wilcoxon signed-rank test). A sig-
nificantly higher expression of ERD3 messenger RNA in
the normal compared with the adjacent neoplastic compo-
nents was found when only the ER-positive subset was
considered, however (n = 8; P = 0.023, Wilcoxon signed-
rank test).
Relative expression of ERD5 messenger RNA in matched
normal and breast tumor tissues
Using primers annealing to sequences in exons 4 and 6 of
WT-ER, we also investigated the relative expression of
ERD5 messenger RNA in these 18 matched cases. Two
PCR products were detected, that migrated at an appar-
ent size of 483 and 344 base pairs, and that have previ-
ously been shown to correspond to WT-ER and ERD5
complementary DNAs, respectively (Fig 3a). As shown in
Fig 3b, a statistically significant higher relative expression
of ERD5 messenger RNA was observed in tumor compo-
nents when this expression was measurable in both
normal and adjacent tumor tissues (n = 15;  P = 0.035,
Wilcoxon signed-rank test).
Discussion
The expression of ERC4, ERD3 and ERD5 variant mes-
senger RNAs relative to WT-ER messenger RNA expres-
sion within adjacent normal and neoplastic human breast
http://breast-cancer-research.com/content/2/1/064
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quantitative reverse transcription PCR assays [18,19,24].
These assays allow the determination of the expression of
ER-a variant messenger RNA relative to WT-ER messen-
ger RNA using a very small amount of starting material,
and offer the advantage of allowing investigators to work
with histopathologically well characterized human breast
tissue regions. It should be noted, however, that the sensi-
tivities of the assays used in this study differed from each
other. The triple-primer PCR assay has previously been
set up to allow the determination of ERC4 relative expres-
sion in tumor samples with very low ER levels, as mea-
sured by ligand-binding assay [24].
We showed that, in samples with a detectable level of
ERC4 messenger RNA using a standardized RNAse pro-
tection assay, the relative expression of this variant to WT-
ER messenger RNA expression was similar to the relative
expression of ERC4 PCR product obtained after triple-
primer PCR [24]. Triple-primer PCR assay applied to the
detection of ERC4 messenger RNA in 18 matched normal
and tumor breast tissues gave a measurable value of
expression in 36 out of the 36 samples studied. This con-
trasts with the detection of 30 out of 36 and 33 out of 36
obtained using ERD3-specific and ERD5-specific primers,
respectively. These differences in sensitivity probably
result from different primer set efficiencies under our
experimental conditions.
A higher ERC4 messenger RNA relative expression in
tumor components compared with the normal adjacent
tissue component has been observed in the ER-
positive/PR-positive subgroup. This result is in agreement
with our previous data [19] obtained by comparing ERC4
messenger RNA expression between independent normal
reduction mammoplasty samples and a group of ER-posi-
tive/PR-positive breast tumors. Even though a higher
ERC4 messenger RNA relative expression was observed
in the tumor component of 12 out of 18 cases, this differ-
ence did not reach statistical significance. This absence of
statistically significant differences might result from the
low number of matched cases studied or from the differ-
ent biology of ER-negative cases. Further studies are
needed to clarify this issue and to draw any conclusion
regarding the expression of ERC4 messenger RNA in ER-
negative samples.
ERC4 variant messenger RNA has previously been shown
[26] to be more highly expressed in ER-positive tumors
that show poor prognostic characteristics (presence of
more than four axillary lymph nodes, tumor size >2 cm,
aneuploid, high percentage S-phase cells) than in ER-pos-
itive tumor with good prognostic characteristics (absence
of axillary lymph node, tumor size <2 cm, diploid, low per-
centage S-phase cells). Moreover, in that previous study, a
higher ERC4 messenger RNA expression was also
observed in ER-positive/PR-negative tumors, as compared
with ER-positive/PR-positive tumors. Interestingly, we
have also recently reported similar levels of expression of
ERC4 messenger RNA in primary breast tumors and their
concurrent axillary lymph node metastases [24]. Taken
together, these data suggest that the putative role of the
ERC4 variant might be important at different phases of
breast tumorigenesis and tumor progression; alteration in
ERC4 messenger RNA expression and resulting modifica-
tions in ER signaling pathway probably occur before
breast cancer cells acquire the ability to metastasize. Tran-
sient expression assays revealed that the protein encoded
by ERC4 messenger RNA was unable to activate the tran-
scription of an estrogen responsive element-reporter gene
or to modulate WT-ER protein activity [17]. The biologic
significance of the changes observed in ERC4 messenger
RNA expression during breast tumorigenesis and tumor
progression therefore remains unclear.
A trend toward a higher relative expression of ERD3 mes-
senger RNA in the normal breast tissue components com-
pared with adjacent neoplastic tissue was found (10 out
of 13 cases), which reached statistical significance when
the ER-positive subgroup only was considered. These
data are in agreement with the recently published report of
Erenburg  et al [20] who showed a decreased relative
expression of ERD3 messenger RNA in neoplastic breast
tissues and breast cancer compared with independent
reduction mammoplasty and breast tumor. Transfection
experiments performed by those investigators showed that
the activation of the transcription of the pS2 gene by
estrogen was drastically reduced in the presence of
increased ERD3 expression. Moreover, ERD3 transfected
MCF-7 human breast cancer cells had a reduced satura-
tion density, exponential growth rate and in vivo invasive-
ness, as compared with control cells. These data led the
authors to hypothesize that the reduction of ERD3 expres-
sion could be a prerequisite for breast carcinogenesis to
proceed. They suggested that if high levels of ERD3 could
attenuate estrogenic effects in normal breast tissue, low
levels might lead to an excessive and unregulated mito-
genic action of estrogen.
We observed a significantly higher relative expression of
ERD5 messenger RNA in breast tumor components com-
pared with matched adjacent normal breast tissue. These
data confirm our previous observations [18] performed on
unmatched normal and neoplastic human breast tissues.
Upregulated expression of this variant has already been
reported in ER-negative/PR-positive tumors, as compared
with ER-positive/PR-positive tumors [15,27], suggesting a
possible correlation between ERD5 messenger RNA
expression and breast tumor progression. Interestingly,
ERD5 messenger RNA can be detected in human pituitary
adenomas, but not in normal pituitary samples [28]. This
underscores the putative involvement of this ER variant in
Breast Cancer Research    Vol 2 No 1 Leygue et al
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that ERD5 could be related to the acquisition of insensitiv-
ity to antiestrogen treatment (ie tamoxifen) [29,30], accu-
mulating data refute a general role for ERD5 in
hormone-resistant tumors [14,25,31,32]. Only ER-positive
pS2-positive tamoxifen resistant tumors have been shown
to express significantly higher levels of ERD5 messenger
RNA, as compared with control tumors [33]. Taken
together, these data suggest that the exact biologic signif-
icance of ERD5 variant expression during breast tumorige-
nesis and breast cancer progression, if any, remains
unclear.
Among all the articles published so far on ER variants, only
one has investigated ER variant expression between
normal and neoplastic matched samples. Okada et al [33]
recently reported a study performed on 15 cases. They
observed an apparent difference in ER variant messenger
RNA expression between adjacent normal and tumor
samples. That study was performed using a less sensitive
PCR approach, however, because PCR products were
stained using ethidium bromide, and no attempt was made
to quantify ER variant messenger RNA expression relative
to WT-ER messenger RNA expression.
In conclusion, we have shown that the relative expression
of ERC4 and ERD5 variant mRNAs was increased in
human breast tumor tissue, as compared with normal adja-
cent tissue, whereas the expression of ERD3 variant mes-
senger RNA was decreased in breast tumor tissues.
These results, which confirm previous data obtained on
independent human breast tissue samples [18,19],
suggest that the expressions of several ER-a variant mes-
senger RNAs are deregulated during human breast
tumorigenesis. Further studies are needed to determine
whether these changes are transposed at the protein
level. Only the use of specific antibodies that are able to
recognize specifically the different ER variant proteins
putatively encoded by these variant messenger RNAs will
allow this issue the be addressed. Furthermore, the puta-
tive role of ER-a variants in the mechanisms that underlie
breast tumorigenesis remain to be determined.
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